GKWIM
DMAC icon

Gerber Kawasaki Wealth & Investment Management’s DiaMedica Therapeutics DMAC Stock Holding History

Gerber Kawasaki Wealth & Investment Management’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-197
Closed – – 497
2021
Q3 		$0 Buy
+197
New +$754 ﹤0.01% 1194

Other funds holding DMAC

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Gerber Kawasaki Wealth & Investment Management's DMAC Position: Q4 2021 in Review

Gerber Kawasaki Wealth & Investment Management sold out of DiaMedica Therapeutics (DMAC) in Q4 2021, closing a stake of 197 shares.

Gerber Kawasaki Wealth & Investment Management first reported a position in DMAC in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 39 funds tracked by Wall St. Rank hold DMAC as of Q4 2021.

  • Gerber Kawasaki Wealth & Investment Management reported no remaining DiaMedica Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Gerber Kawasaki Wealth & Investment Management sold 197 DiaMedica Therapeutics shares in Q4 2021.
  • Gerber Kawasaki Wealth & Investment Management first reported a position in DiaMedica Therapeutics in Q3 2021 and held it in 1 quarter.
  • Gerber Kawasaki Wealth & Investment Management's DiaMedica Therapeutics position peaked at $0 in Q3 2021.
  • 39 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q4 2021.

Based on Gerber Kawasaki Wealth & Investment Management's 13F filing for Q4 2021, filed 11 Feb 2022.